Currently out of the existing stock ratings of Asthika Goonewardene, 93 are a BUY (83.04%), 18 are a HOLD (16.07%), 1 are a SELL (0.89%).

Asthika Goonewardene

Work Performance Price Targets & Ratings Chart

Analyst Asthika Goonewardene, currently employed at TRUIST, carries an average stock price target met ratio of 43.93% that have a potential upside of 34.64% achieved within 153 days.

Asthika Goonewardene’s has documented 216 price targets and ratings displayed on 25 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MRUS, Merus BV at 28-Sep-2025.

Wall Street Analyst Asthika Goonewardene

Analyst best performing recommendations are on IMGN (IMMUNOGEN).
The best stock recommendation documented was for ALLO (ALLOGENE THERAPEUTICS) at 4/13/2020. The price target of $29 was fulfilled within 11 days with a profit of $5.58 (23.83%) receiving and performance score of 21.66.

Average potential price target upside

of $59 (73.04%) on TIL (INSTIL BIO).
of $30.81 (63.99%) on MRUS (MERUS BV).
of $29.04 (46.05%) on NXTC (NEXTCURE ).

ALLO Allogene Therapeutics CELU Celularity CGEN Compugen EXEL Exelixis GMAB Genmab AS HARP Harpoon Therapeutics IGMS IGM Biosciences IOVA Iovance Biotherapeutics STRO Sutro Biopharma TCRR Tcr2 Therapeutics HOOK Hookipa Pharma NXTC NextCure AUTL Autolus Therapeutics Ltd TIL Instil Bio SGEN Seagen ACET Adicet Bio ACLX Arcellx IMGN ImmunoGen MRSN Mersana Therapeutics CRBU Caribou Biosciences GILD Gilead Sciences MRUS Merus BV CRGX CARGO Therapeutics, Common Stock BNTX BioNTech SE LEGN Legend Biotech Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Brian Cheng (JPMORGAN)